SEC Form 4 · accession 0001104659-15-018601
STEMLINE THERAPEUTICS INC · STML
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Gionco
Officer — Chief Accounting Officer
Period of report
Mar 6, 2015
Accepted (ET)
Mar 10, 2015 · 5:54 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001264587
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 6, 2015 | A | 11,569 | $0.00 | A | 38,258 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy)F2 | $15.75 | Mar 6, 2015 | A | 32,841 | A | Mar 6, 2016 | Mar 6, 2025 | Common Stock | 32,841 | 32,841 | D |
Explanation of responses
- F1The 11,569 restricted shares will vest in four installments as follows: 2,893 shares on March 6, 2016; 2,892 shares on March 6, 2017; 2,892 shares on March 6, 2018; and 2,892 shares on March 6, 2019.
- F2The 32,841 options will vest in four installments as follows: 8,211 shares on March 6, 2016; 8,210 shares on March 6, 2017; 8,210 shares on March 6, 2018; and 8,210 shares on March 6, 2019.